Tagged with HE

Ecuador Juan Carlos Galarza, executive director of Ecuador’s National Health Regulation, Control and Surveillance Agency (ARCSA), discusses the multiple procedural improvements that the Agency has recently implemented with the objective of increasing its international recognition, the benefits of these actions for Ecuadorians – who will have faster and safer access to…

UK Much of the new inward investment in the UK from international pharmaceutical companies is from those that wish their discovery science to be in close adjacency to the most successful basic science programmes in biomedicinein the world. The co-location of pharmaceutical discovery sciences adjacent to the best universities (AstraZeneca in Cambridge, Novo Nordisk…

UK Simon Gillespie of the British Heart Foundation (BHF), the UK’s leading national heart charity, outlines the organization’s mission, the issues surrounding translational research, and the potential impact of Brexit on the UK life sciences landscape.   One of the key matters for us is that we don’t have direct customers.…

UK Hilary Evans of Alzheimer’s Research UK (ARUK), the UK’s leading national research charity in the field of dementia, discusses her organization’s mission; the growing awareness of, and investment in, dementia research, care and diagnosis; and the enduring importance of international collaboration.   In the UK, when people want to help…

Brazil “Brazil undoubtedly holds great development opportunities for the global pharmaceutical and healthcare industries,” boldly states Minister of Health Ricardo Barros, “and we hope to gain the trust of an increasing number of international investors and jointly work on improving the healthcare products and services available to our 207 million Brazilian…

Baltics SIFFA’s Valters Bolēvics discusses Latvia’s competitiveness in embracing medical innovations, current healthcare reforms, and the country’s enduring potential as a pharmaceutical investment destination. The Association of International Research-based Pharmaceutical Manufacturers (SIFFA) was initially founded in 1996 to act as a united voice for five multinationals that had penetrated the local…

Canada Whitney Green candidly describes what first surprised him as an American coming to Canada to head up operations as president and general manager of Roche Diagnostics Canada. He highlights the benefits the innovative portfolio of Roche Diagnostics can bring to Canada, its potential in driving forward personalized healthcare and the…

Canada Mark Smithyes, president of Labtician Théa, highlights the company’s ambition to become the leader and preferred partner to optometrists and ophthalmologists in Canada by launching products from Laboratoires Théa’s innovative portfolio and building on Labtician Ophthalmics’ excellent reputation. Mark, what were the decisive pinpoints behind the joint venture between Labtician…

Ecuador Angel Guevara, molecular biologist and professor at the Central University of Ecuador (UCE), discusses Ecuador’s potential as a clinical trial destination, a diverse tropical country with high prevalence of infectious disease and educated healthcare professionals. He explains the differences between public and private healthcare services, notably from the point of…

Lithuania Daina Klepone, managing director at Enterprise Lithuania, explains the opportunities Lithuania can offer to healthcare businesses and how their organization can help them enter the market. Moreover, she introduces the ‘Life Sciences Baltics’ event, and its key role to promote the industry in the Baltic region. Could you please start…

Serbia Serbia macroeconomic factsheet including data on population, GDP, education and life expectancy. Serbia has risen 50 places in the World Bank’s ‘Doing Business’ rankings from 93rd in 2014 to 43rd in 2018. Serbia’s GDP per capita between 2008 and 2016. International comparison of healthcare spending growth and GDP growth between…

Pharma The top 10 pharmaceutical companies in Canada for 2016 in terms of total sales and market share. Johnson & Johnson leads the way with USD 2.93 billion in sales, followed by Novartis with USD 1.24 billion and TEVA with USD 1.19 billion.